All In MedTech

Device Trial Radar · NCT02701283

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 2,223 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,223

Actual

Start

Mar 2016

Primary completion

Apr 2021

Study completion Jun 2029

Sponsor

Lead sponsor
Medtronic CardiovascularPublic (MDT)
Sponsor type
Industry
First posted
Mar 8, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR. The purpose of the expanded use addendum to the Medtronic TAVR in Low Risk Patients Trial protocol is to conclude the randomized phase of the trial and initiate the single-arm, non-randomized, continued access phase of the trial.

Conditions

  • Aortic Valve Stenosis

Interventions

  • Medtronic Transcatheter Aortic Valve Replacement SystemsDevice

    Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems

  • Surgical Aortic Valve Replacement (SAVR)Device

    Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: All Cause Mortality or Disabling Stroke Rate at 24 Months, Randomized Controlled Trial Safety: All Cause Mortality or All Stroke Rate at 12 Months, Continued Access StudyTime frame: Randomized Controlled Trial - 24 months Continued Access Study - 12 months

Locations

87 sites in 7 countries. Site status is shown where the registry gives one.

  • Abrazo Arizona Heart Hospital

    Phoenix, Arizona

  • Scripps Memorial Hospital La Jolla

    La Jolla, California

  • University of Southern California University Hospital

    Los Angeles, California

84 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.